Evaluating the costs and benefi ts of using combination therapies

Medical Journal of Australia

Volumn 200, Issue 9, 2014, Pages 518-520

  Clarke, Philip M ^a   Avery, Alex B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG THERAPY; ECONOMICS; HUMAN;

AUSTRALIA; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG THERAPY; HUMANS;

EID: 84903795974     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.00199     Document Type: Article

References (11)

1. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.
2. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated December 2010. http://www.heartfoundation.org.au/SiteCollectionDocuments/HypertensionGuidelines 2008to2010Update.pdf (accessed Apr 2014).
3. Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36 Suppl 2: S139-S144.
4. Thom S, Poulter N, Field J, et al; UMPIRE Collaborative Group. Eff ects of a fi xed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918-929.
5. Pharmaceutical Benefi ts Advisory Committee. Guidelines for preparing, submissions to the Pharmaceutical, Benefi ts Advisory Committee. Version 4.4. 2008. http://www.pbac.pbs.gov.au (accessed Apr 2014).
6. National Institute for Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. NICE technology appraisal guidance 132. London: NICE, 2007. http://www.nice.org.uk/nicemedia/live/11886/38799/38799.pdf (accessed Apr 2014).
7. Australian Government Department of Health and Ageing. Pharmaceutical Benefi ts Scheme expanded and accelerated price disclosure arrangements. Procedural and operational guidelines. 2010. http://www.pbs.gov.au/ industry/pricing/eapd/eapd-guidelines.pdf (accessed Apr 2014).
8. Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2011; (1): CD005158.
9. Clarke PM. The pricing of statins and implications for Pharmaceutical Benefi ts Scheme expenditure. Med J Aust 2013; 198: 260.
10. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336: 251-254.
11. Australian Government Department of Health and Ageing. Strategic review of health and medical research: better health through research. Canberra: Commonwealth of Australia, 2013. http://www.mckeonreview.org.au/downloads/Strategic_Review_of_Health_and_Medical_Research_ Feb_2013-Final_Report.pdf (accessed Apr 2014).